Join our comprehensive program tailored to provide personalized education based on your existing knowledge on the latest advancements in B7-H3 checkpoint inhibitors for the treatment of small cell lung cancer (SCLC). Explore cutting-edge developments in novel B7-H3 inhibitors, gain updates on their evolving clinical profiles, and review their potential placement within therapeutic algorithms. Test your knowledge, receive real-time feedback, and create your own unique experience available with a curated, downloadable resource upon completion based on your current level of knowledge.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/targeting-b7-h3-latest-safety-efficacy-data-emerging-b7-h3-targeted-agents-sclc
- Start Date: 2024-09-27 05:00:00
- End Date: 2024-09-27 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 74750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest